ALX Oncology (ALXO) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ALX Oncology (ALXO) has outperformed Protara Therapeutics (TARA) over the past year, losing 35.6% versus a loss of 47.7%. Over five years, TARA leads with a -61.3% price change compared with -97.9% for ALXO. ALX Oncology is the larger company by market cap ($172.8 million vs $162.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | TARA |
|---|---|---|
| Share price | $1.25 | $2.76 |
| Market cap | $172.85M | $162.81M |
| 1-day change | +5.93% | +3.96% |
| YTD return | +10.62% | -50.28% |
| 1-year return | -35.57% | -47.73% |
| 5-year return | -97.88% | -61.26% |
| EPS (TTM) | $-1.13 | $-1.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $7.82 |
| 52-week low | $1.05 | $2.51 |
| Distance from 52-week high | -53.01% | -64.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +268.00% | +833.21% |
| Average volume | 1.04M | 814.80K |
| Shares outstanding | 138.28M | 59.10M |
| Employees | 48 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALXO has outperformed TARA by 12.2 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
ALXO vs TARA FAQ
Which is bigger, ALX Oncology or Protara Therapeutics?
ALX Oncology (ALXO) is larger, with a market capitalization of $172.85M compared with $162.81M for Protara Therapeutics (TARA).
Which stock has performed better over the past year, ALXO or TARA?
ALXO returned -35.57% over the past 12 months, compared with -47.73% for TARA (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Protara Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for ALX Oncology and Biotechnology: Biological Products (No Diagnostic Substances) for Protara Therapeutics.